Rituximab: Ongoing and future clinical development

Antonio J Grillo-López(Roche (Switzerland)), Mark Benyunes(Roche (Switzerland)), Eric Hedrick(Florida Hospital Cancer Institute), Michelle Rashford(Roche (Switzerland))

Seminars in Oncology

February 1, 2002

10.1053/sonc.2002.30145

Cited by 185

Related Papers

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

|New England Journal of Medicine|2013|2.2k

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

|Journal of Clinical Oncology|2002|1.2k

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

|Journal of Clinical Oncology|2012|1.1k

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

|Journal of Clinical Oncology|2008|695

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

|Journal of Clinical Oncology|2008|623